Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants aged ≥ 19 years~* Participants who have voluntarily given written consent to participate in this clinical trial~* Participants with LDL-C ≤ 250mg/dL and TG \< 500mg/dL at Visit 1~* Participants with LDL-C ≤ 250mg/dL, TG \< 500 mg/dL and satisfied criteria according to cardiovascular risk category at Visit 2 (after at least 4 weeks of TLC)~Exclusion Criteria:~* Patients with active liver disease and severe liver impairment~* Patients with severe renal failure (eGFR \< 30 mL/min/1.73 m2 at Visit 1)~* Patients with type I diabetes or uncontrolled type 2 diabetes~* Patients with acute hypertension or uncontrolled hypertension (sitSBP ≥ 180 mmHg or sitDBP ≥ 110 mmHg at Visit 1)~* Patients with symptomatic orthostatic hypotension~* Patients with NYHA class III\~IV heart failure, CCSA class III\~IV angina, ventricular arrhythmia, severe hemorrhagic or ischemic cerebrovascular diseases, transient ischemic attacks (TIAs), acute coronary syndrome or a history of angioplasty, percutaneous coronary intervention, or coronary artery bypass surgery within six months before Visit 1.~* Patients who were diagnosed with a malignant tumor within five years before Visit.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HGP1910 (Type: EXPERIMENTAL): None
- HCP1903 (Type: EXPERIMENTAL): None
- HGP1909 (Type: ACTIVE_COMPARATOR): None
- HGP1911 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).